JP4709741B2 - Process for producing pyridine-substituted aminoketal derivatives - Google Patents

Process for producing pyridine-substituted aminoketal derivatives Download PDF

Info

Publication number
JP4709741B2
JP4709741B2 JP2006501606A JP2006501606A JP4709741B2 JP 4709741 B2 JP4709741 B2 JP 4709741B2 JP 2006501606 A JP2006501606 A JP 2006501606A JP 2006501606 A JP2006501606 A JP 2006501606A JP 4709741 B2 JP4709741 B2 JP 4709741B2
Authority
JP
Japan
Prior art keywords
formula
hydroxide
acetylpyridine
sodium
chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006501606A
Other languages
Japanese (ja)
Other versions
JP2006518716A (en
JP2006518716A5 (en
Inventor
ハンス−ヴォルフラム・フレミング
ゲーアハルト・コルプ
イュルゲン・ミュラー−レハール
ヴァルター・ヴェーバー
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2006518716A publication Critical patent/JP2006518716A/en
Publication of JP2006518716A5 publication Critical patent/JP2006518716A5/ja
Application granted granted Critical
Publication of JP4709741B2 publication Critical patent/JP4709741B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/51Acetal radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Description

本発明は、式(I)のピリジニル−置換ジアルコキシアミノエタン誘導体の製造法、及び本発明の製造法の中間体を提供する。

Figure 0004709741
The present invention provides a process for the preparation of pyridinyl-substituted dialkoxyaminoethane derivatives of formula (I) and intermediates of the process of the invention.
Figure 0004709741

式(I)の化合物は活性な薬剤成分の製造における中間体である。例えば、特許文献1は式(I)の化合物の誘導体の合成を記載し、ここでピリジン基は3−位で置換されそしてR’は(C1−C3)−アルキルである。特許文献1によると、これらの誘導体から出発して、式(II)の化合物が得られる。

Figure 0004709741
The compounds of formula (I) are intermediates in the production of active pharmaceutical ingredients. For example, Patent Document 1 describes the synthesis of derivatives of compounds of formula (I), wherein the pyridine radical is substituted in the 3-position and R 'is (C 1 -C 3) - alkyl. According to Patent Document 1, starting from these derivatives, compounds of the formula (II) are obtained.
Figure 0004709741

更に、式(I)の化合物は式(III)のピリジノイミダゾール誘導体の製造用の構成単位として使用される(非特許文献1)。

Figure 0004709741
式中、R”はH、SHである。 Further, the compound of the formula (I) is used as a structural unit for producing a pyridinoimidazole derivative of the formula (III) (Non-patent Document 1).
Figure 0004709741
In the formula, R ″ is H or SH.

式(III)のピリジノイミダゾール誘導体は新規なマクロライド抗生物質、例えばテリスロマイシンの製造に使用された(特許文献2)。   The pyridinoimidazole derivative of the formula (III) has been used for the production of novel macrolide antibiotics, for example tethromycin (patent document 2).

式(I)の化合物の公知の製造法は、アルコール溶液中でのケトキシムのp−トルエンスルホン酸エステルへのアルカリ金属アルコキシドの作用に基づき、例えば式(I)のアミノケタール誘導体が環式アミノケトン類の製造中に中間体として生じる(非特許文献2)。   Known methods for preparing compounds of formula (I) are based on the action of alkali metal alkoxides on ketoxime p-toluenesulfonate in alcoholic solutions, for example aminoketal derivatives of formula (I) are cyclic aminoketones It occurs as an intermediate during the production of (Non-patent Document 2).

式(I)の1−(ピリジニル)−1,1−ジアルコキシ−2−アミノエタン誘導体の製造は特許文献1に記載され、例えば式(IV)の1−(3−ピリジニル)−1,1−ジエトキシ−2−アミノエタンニ塩酸塩を使用して下記の3段階工程で製造する:

Figure 0004709741
The preparation of 1- (pyridinyl) -1,1-dialkoxy-2-aminoethane derivatives of formula (I) is described in US Pat. Prepared in the following three-step process using diethoxy-2-aminoethane dihydrochloride:
Figure 0004709741

この方法では、式(V)の3−アセチルピリジンをまずメタノール中で塩化ヒドロキシルアンモニウムでオキシム化する。得られた式(VI)の3−アセチルピリジンオキシムを溶媒変更によりピリジンに変換し、そして多くの蒸留操作及び新たなピリジン(水含量<5モル%)の添加により乾燥する。

Figure 0004709741
In this method, 3-acetylpyridine of formula (V) is first oximed with hydroxylammonium chloride in methanol. The resulting 3-acetylpyridine oxime of formula (VI) is converted to pyridine by changing the solvent and dried by addition of many distillation operations and addition of fresh pyridine (water content <5 mol%).
Figure 0004709741

或いは、オキシム化をピリジン中で直接実施し、そして乾燥を同じように行う。式(VI)の3−アセチルピリジンオキシムの塩酸塩とピリジンとの得られた混合物を引き続き式(VII)の塩化トシルと反応させて、水との混合物から沈殿した式(VIII)の3−アセチルピリジントシルオキシムを得、分離する。

Figure 0004709741
Alternatively, oximation is carried out directly in pyridine and drying is carried out in the same way. The resulting mixture of 3-acetylpyridine oxime hydrochloride of formula (VI) and pyridine is subsequently reacted with tosyl chloride of formula (VII) to precipitate 3-acetyl of formula (VIII) precipitated from the mixture with water. Pyridine tosyl oxime is obtained and separated.
Figure 0004709741

得られた式(VIII)のトシルオキシムを引き続きエタノール中でカリウムエトキシドとネーバー転移で反応させて、アミノケタールを得る。得られたp−トルエンスルホン酸カリウム塩をメチルtert−ブチルエーテルで希釈した後、濾過し、濾過した溶液をエーテルに溶かした塩化水素と混合する。これで式(IV)の1−(3−ピリジニル)−1,1−ジエトキシ−2−アミノエタンニ塩酸塩がオレンジ色固体として沈殿する。   The resulting tosyl oxime of formula (VIII) is subsequently reacted with potassium ethoxide in ethanol by Naver transfer to give the amino ketal. The obtained p-toluenesulfonic acid potassium salt is diluted with methyl tert-butyl ether, filtered, and the filtered solution is mixed with hydrogen chloride dissolved in ether. This precipitates 1- (3-pyridinyl) -1,1-diethoxy-2-aminoethanedihydrochloride of formula (IV) as an orange solid.

特許文献1によると、単離した生成物の純度は1H及び13C NMRデータを用いてのみ推定することができ、未知の不純物の結果、95%超である。更なる反応のため、該アミノケタールニ塩酸塩(IV)を水に懸濁させ、水酸化ナトリウム溶液と混合して、アミノケタールを、次のカップリング反応に必要な遊離塩基として製造する。 According to U.S. Pat. No. 6,057,059, the purity of the isolated product can only be estimated using 1 H and 13 C NMR data and is greater than 95% as a result of unknown impurities. For further reaction, the amino ketal dihydrochloride (IV) is suspended in water and mixed with sodium hydroxide solution to produce the amino ketal as the free base required for the next coupling reaction.

上記の方法は工業規模に拡大するにはいくつかの不利な点がある。第1に、得られた中間体の各々を蒸留操作により乾燥しなければならない。第2に、式(VIII)の3−アセチルピリジントシルオキシム中間体は室温より高い温度で長く保存すると極めて容易に分解して大量のエネルギーを放出する(3−アセチルピリジントシルオキシムの分解エネルギー約1000J/g、非特許文献2中のトルエンスルホン酸ケトオキシムエステルの貯蔵に関する警告参照)。第3に、このようにして製造した1−(3−ピリジニル)−1,1−ジエトキシ−2−アミノエタンニ塩酸塩は副生物が混入しており、強い着色により確認される。第4に、遊離の1−(3−ピリジニル)−1,1−ジエトキシ−2−アミノエタンを得るためには、単離した塩(IV)を追加のステップで補助の塩基を用いて遊離しなければならない。第5に、工程中に頻繁な溶媒交換がある。従って溶媒混合物を非常に費用をかけて再び処理しなければならず、それは環境汚染になる。
米国特許第5,792,871号 米国特許第5,635,485号 J.Am.Soc.,1938年,753−755頁 F.Moeller:Amine durch Umiagerungsreaktionen(Neber−Umiagerung)[Amines by rearrangement reactions (Neber rearrangement)],Houben−Weyl 11/1:Stickstoffverbindungen II[Nitrogen compounds 11](1957年),903−905頁
The above method has several disadvantages for scaling up to an industrial scale. First, each of the resulting intermediates must be dried by a distillation operation. Secondly, the 3-acetylpyridine tosyloxime intermediate of formula (VIII) decomposes very easily upon release for a long time at a temperature higher than room temperature and releases a large amount of energy (the decomposition energy of 3-acetylpyridine tosyloxime is about 1000 J / G, see warning on storage of toluenesulfonic acid ketoxime ester in Non-Patent Document 2). Thirdly, 1- (3-pyridinyl) -1,1-diethoxy-2-aminoethanedihydrochloride prepared in this way is contaminated with by-products and is confirmed by strong coloration. Fourth, to obtain free 1- (3-pyridinyl) -1,1-diethoxy-2-aminoethane, the isolated salt (IV) must be liberated with an auxiliary base in an additional step. I must. Fifth, there is frequent solvent exchange during the process. The solvent mixture must therefore be processed again at a very high cost, which becomes an environmental pollution.
US Pat. No. 5,792,871 US Pat. No. 5,635,485 J. et al. Am. Soc. 1938, 753-755. F. Moeller: Amine durch Umagerun sreaktionen (Never-Umagerung) [Amines by rearrangement reactions (Neber rienrangement) (Never-90 rend)

本発明の目的は、式(I)の化合物を合成するためのより効率的且つ安全な方法を見出すことである。   The object of the present invention is to find a more efficient and safe method for the synthesis of compounds of formula (I).

従って、本発明は式(I)の1−ピリジニル−1,1−ジアルコキシ−2−アミノエタン誘導体であって、R1及びR2はそれぞれ独立して(C1−C6)−アルキル(ここで該アルキル基は直鎖又は分岐鎖であることができる)であるか、又はR1及びR2は酸素原子と一緒に環式ケタール(ここでR1及びR2は一緒になって(C2−C4)−アルキリデン基である)を形成し、ピリジン基は2−、3−又は4−位、好ましくは3−位が置換されている上記誘導体の製造法を提供し、該製造法は、
工程(a)で、式(V)のアセチルピリジンを、ヒドロキシルアンモニウム化合物、例えば塩化ヒドロキシルアンモニウム又は硫酸ヒドロキシルアンモニウム、の水溶液、又はヒドロキシルアミンの水溶液を用いて、同時に又は後にMn+を含む無機塩基を添加して、式(IX)のアセチルピリジンオキシム金属塩(ここでnは1又は2、そしてMはn=1の場合はアルカリ金属、又はn=2の場合はアルカリ土類金属であり、好ましくはLi+、Na+、K+又はCa2+である)に変換することを含む。

Figure 0004709741
Accordingly, the present invention is a 1-pyridinyl-1,1-dialkoxy-2-aminoethane derivative of the formula (I), wherein R 1 and R 2 are each independently (C 1 -C 6 ) -alkyl (here The alkyl group can be linear or branched) or R 1 and R 2 together with an oxygen atom are cyclic ketals (where R 1 and R 2 together (C 2 -C 4) - form an alkylidene group is), pyridine groups 2-, 3- or 4-position, preferably 3-position to provide a process for producing the derivatives substituted, said process Is
In step (a), an acetylpyridine of formula (V) is converted to an inorganic base containing M n + simultaneously or after using an aqueous solution of a hydroxylammonium compound, for example hydroxylammonium chloride or hydroxylammonium sulfate, or an aqueous solution of hydroxylamine. In addition, an acetylpyridine oxime metal salt of formula (IX), where n is 1 or 2, and M is an alkali metal when n = 1, or an alkaline earth metal when n = 2, preferably Is Li + , Na + , K + or Ca 2+ ).
Figure 0004709741

1及びR2は好ましくは(C1−C6)−アルキル基である。R1及びR2が同じでありそしてそれぞれ(C1−C6)−アルキル基であるのが特に好ましい。(C1−C6)−アルキル基は例えば、メチル、エチル、n−プロピル、イソプロピル、n−ブチル、イソブチル又はn−ヘキシルである。 R 1 and R 2 are preferably (C 1 -C 6 ) -alkyl groups. It is particularly preferred that R 1 and R 2 are the same and each is a (C 1 -C 6 ) -alkyl group. A (C 1 -C 6 ) -alkyl group is, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or n-hexyl.

(C2−C4)−アルキリデン基を含む環式ケタールは、例えば[1,3]ジオキソラン又は[1,3]ジオキサン基である。 Cyclic ketals containing a (C 2 -C 4 ) -alkylidene group are for example [1,3] dioxolane or [1,3] dioxane groups.

製造はバッチ式又は連続式で単一又は複数成分計量添加法(metering)により行うことができる。式(IX)の化合物は単離するか又は溶液若しくは懸濁液として更に加工することができる。   Manufacture can be performed batchwise or continuously by single or multiple component metering. The compound of formula (IX) can be isolated or further processed as a solution or suspension.

n+は例えばLi+、Na+、K+又はCa2+である。Mn+を含む無機塩基は、例えばアルカリ金属若しくはアルカリ土類金属水酸化物、アルカリ金属若しくはアルカリ土類金属炭酸塩、アルカリ金属若しくはアルカリ土類金属炭酸水素塩、又はそれらの混合物であり、好ましくは水酸化リチウム、水酸化ナトリウム、水酸化カリウム、水酸化カルシウム、炭酸ナトリウム、炭酸水素ナトリウム、又は炭酸カリウムである。 M n + is, for example, Li + , Na + , K + or Ca 2+ . The inorganic base containing M n + is, for example, an alkali metal or alkaline earth metal hydroxide, an alkali metal or alkaline earth metal carbonate, an alkali metal or alkaline earth metal hydrogen carbonate, or a mixture thereof, preferably Lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, sodium bicarbonate, or potassium carbonate.

アセチルピリジン100モルに対しては、ヒドロキシルアミン又はヒドロキシルアンモニウム化合物98−120モル、更に好ましくは99−101モル;そしてまたM+を含む無機塩基200−300モル、更に好ましくは200−220モル、又はM2+を含む無機塩基100−150モル、更に好ましくは100−110モルを使用することが好ましい。 For 100 moles of acetylpyridine, 98-120 moles of hydroxylamine or hydroxylammonium compound, more preferably 99-101 moles; and also 200-300 moles, more preferably 200-220 moles, of an inorganic base containing M + , or It is preferable to use 100 to 150 mol, more preferably 100 to 110 mol, of an inorganic base containing M 2+ .

工程ステップ(b)で、式(IX)のアセチルピリジン金属塩の水溶液、水性懸濁液又は単離された固体を、水不溶性又はわずかに水可溶性の適当な溶媒中の、脱離基Yを含むp−トルエンスルホン酸誘導体(X)

Figure 0004709741
(式中、YはF、Cl又はBr、好ましくはCl)の溶液と反応させて、式(XI)のアセチルピリジントシルオキシムを得る:
Figure 0004709741
In process step (b), an aqueous solution, aqueous suspension or isolated solid of an acetylpyridine metal salt of formula (IX) is removed with a leaving group Y in a suitable solvent which is insoluble or slightly soluble in water. Containing p-toluenesulfonic acid derivative (X)
Figure 0004709741
(Wherein, Y is F, Cl or Br, preferably Cl) by the solution and reaction of obtaining the acetylpyridine tosyl oxime of the formula (XI):
Figure 0004709741

反応は水と適当な水不溶性溶媒との2相混合物中で進行し、そして反応は場合によっては1種又はそれ以上の相間移動触媒、例えば第4級アンモニウム塩又はホスホニウム塩、好ましくは式(XII)の第4級アンモニウム塩又は式(XIII)のホスホニウム塩、又は式(XII)若しくは式(XIII)の塩の水和物、の使用により進行する。

Figure 0004709741
The reaction proceeds in a two-phase mixture of water and a suitable water-insoluble solvent, and the reaction is optionally one or more phase transfer catalysts such as quaternary ammonium salts or phosphonium salts, preferably of formula (XII ) Quaternary ammonium salts or phosphonium salts of formula (XIII) or hydrates of salts of formula (XII) or formula (XIII).
Figure 0004709741

ここで、R3ないしR10は同じ又は異なり、そしてそれぞれ独立して
a)直鎖又は分岐鎖の(C1−C20)−アルキル、
b)ベンジル、又は
c)フェニル、そして
-はアニオン、例えばフッ素、塩素、臭素、ヨウ素、水酸、硫酸水素、テトラフルオロホウ酸、酢酸、トリフルオロメタンスルホン酸、硝酸、ヘキサフルオロアンチモン酸イオンである。
In which R 3 to R 10 are the same or different and are each independently a) a linear or branched (C 1 -C 20 ) -alkyl;
b) benzyl, or c) phenyl, and X is an anion such as fluorine, chlorine, bromine, iodine, hydroxy acid, hydrogen sulfate, tetrafluoroboric acid, acetic acid, trifluoromethanesulfonic acid, nitric acid, hexafluoroantimonate ion. is there.

2相混合物中の反応は1種又はそれ以上の相間移動触媒を使用して実施するのが好ましいが、相間移動触媒なしでも進行する。   The reaction in the two-phase mixture is preferably carried out using one or more phase transfer catalysts, but it proceeds even without a phase transfer catalyst.

工程(b)はバッチ式又は連続的に行うことができるが、連続的に行うのが好ましく、その場合、安全性の観点から重要である式(XI)の化合物の濃度は低く維持する。得られた溶媒と水性相との混合物は引き続き相分離の通常の方法により分離する。水性相は溶解した使用金属塩を含む。水性相は生物学的精製に送られる。場合によっては、水性相は引き続き適当な水不溶性溶媒で1回又はそれ以上洗浄し、そして溶媒相を合わせそして一緒に更に加工する。溶媒相は式(XI)の化合物を含む。   Step (b) can be carried out batchwise or continuously, but is preferably carried out continuously, in which case the concentration of the compound of formula (XI), which is important from the viewpoint of safety, is kept low. The resulting mixture of solvent and aqueous phase is subsequently separated by conventional methods of phase separation. The aqueous phase contains the used metal salt dissolved. The aqueous phase is sent for biological purification. In some cases, the aqueous phase is subsequently washed one or more times with a suitable water-insoluble solvent, and the solvent phases are combined and further processed together. The solvent phase contains a compound of formula (XI).

工程(b)において、式(IX)の3−アセチルピリジンオキシム塩100モルに対しては、相間移動触媒を0.1−50モル、好ましくは0.2−10モル使用するのが好ましい。   In the step (b), it is preferable to use 0.1-50 mol, preferably 0.2-10 mol, of the phase transfer catalyst with respect to 100 mol of the 3-acetylpyridine oxime salt of the formula (IX).

式(XXII)の第4級アンモニウム塩の例は、臭化テトラメチルアンモニウム、塩化テトラメチルアンモニウム、塩化テトラエチルアンモニウム、塩化n−ブチルトリエチルアンモニウム、塩化メチルトリイソプロピルアンモニウム、塩化メチルトリ−n−ブチルアンモニウム(Aliquat(登録商標)175)、臭化メチルトリ−n−ブチルアンモニウム、硫酸水素メチルトリ−n−ブチルアンモニウム、塩化メチルテトラ−n−ブチルアンモニウム、塩化メチルトリ−n−オクチルアンモニウム(Aliquat(登録商標)336)、水酸化メチルトリ−n−オクチルアンモニウム、塩化メチルトリカプリルアンモニウム、水酸化メチルトリカプリルアンモニウム、塩化ジメチルベンジル(C8−C18)−アルキル、塩化テトラ−n−プロピルアンモニウム、塩化トリエチルヘキシルアンモニウム、塩化トリエチル−n−オクチルアンモニウム、臭化トリエチル−n−オクチルアンモニウム、臭化トリエチル−n−デシルアンモニウム、臭化トリエチル−n−ヘキサデシルアンモニウム、塩化フェニルトリエチルアンモニウム、臭化エチルトリ−n−オクチルアンモニウム、塩化テトラ−n−ブチルアンモニウム、臭化テトラ−n−ブチルアンモニウム、塩化テトラ−n−ブチルアンモニウム、硫酸水素テトラ−n−ブチルアンモニウム、ヨウ化テトラメチルアンモニウム、水酸化テトラメチルアンモニウム5水和物、水酸化テトラメチルアンモニウム、臭化メチルトリエチルアンモニウム、塩化テトラメチルアンモニウム1水和物、臭化テトラメチルアンモニウム、ヨウ化テトラメチルアンモニウム、テトラフルオロホウ酸テトラメチルアンモニウム、臭化(n−ヘキシル)トリメチルアンモニウム、塩化フェニルトリメチルアンモニウム、ヨウ化フェニルトリメチルアンモニウム、塩化ベンジルトリメチルアンモニウム、ヨウ化ベンジルトリメチルアンモニウム、水酸化ベンジルトリメチルアンモニウム、臭化(n−オクチル)トリメチルアンモニウム、臭化(N−ノニル)トリメチルアンモニウム、臭化テトラ−n−プロピルアンモニウム、ヨウ化フェニルトリエチルアンモニウム、臭化(n−デシル)トリメチルアンモニウム、塩化ベンジルトリエチルアンモニウム、臭化ベンジルトリエチルアンモニウム、テトラフルオロホウ酸ベンジルトリエチルアンモニウム、水酸化ベンジルトリエチルアンモニウム、塩化(n−ドデシル)トリメチルアンモニウム、臭化(n−ドデシル)トリメチルアンモニウム、塩化ベンジルトリ−n−プロピルアンモニウム、臭化テトラ−n−ブチルアンモニウム、ヨウ化テトラ−n−ブチルアンモニウム、酢酸テトラ−n−ブチルアンモニウム、硫酸水素テトラ−n−ブチルアンモニウム、水酸化テトラ−n−ブチルアンモニウム、トリフルオロメタンスルホン酸テトラ−n−ブチルアンモニウム、塩化(n−テトラデシル)トリメチルアンモニウム、臭化(n−テトラデシル)トリメチルアンモニウム、臭化(n−ヘキサデシル)トリメチルアンモニウム、塩化テトラ−n−ペンチルアンモニウム、ヨウ化テトラ−n−ペンチルアンモニウム、塩化ベンジルトリn−ブチルアンモニウム、臭化ベンジルトリ−n−ブチルアンモニウム、塩化(n−ヘキサデシル)ピリジニウム1水和物、臭化(n−ヘキサデシル)ピリジニウム1水和物、臭化テトラ−n−ヘキシルアンモニウム、硫酸水素テトラ−n−ヘキシルアンモニウム、臭化テトラ−n−オクチルアンモニウム、ヨウ化テトラ−n−ドデシルアンモニウム又は硝酸テトラ−n−ドデシルアンモニウムである。 Examples of quaternary ammonium salts of formula (XXII) are tetramethylammonium bromide, tetramethylammonium chloride, tetraethylammonium chloride, n-butyltriethylammonium chloride, methyltriisopropylammonium chloride, methyltri-n-butylammonium chloride ( Aliquat (R) 175), methyltri-n-butylammonium bromide, methyltri-n-butylammonium hydrogen sulfate, methyltetra-n-butylammonium chloride, methyltri-n-octylammonium chloride (Aliquat (R) 336) , hydroxide methyltri -n- octyl ammonium, methyl tricapryl ammonium chloride, methyl tricapryl ammonium hydroxide, chloride dimethylbenzyl (C 8 -C 18) - alkyl, chlorides tetra -N-propylammonium chloride, triethylhexylammonium chloride, triethyl-n-octylammonium chloride, triethyl-n-octylammonium bromide, triethyl-n-decylammonium bromide, triethyl-n-hexadecylammonium bromide, phenyltriethyl chloride Ammonium, ethyl tri-n-octylammonium bromide, tetra-n-butylammonium chloride, tetra-n-butylammonium bromide, tetra-n-butylammonium chloride, tetra-n-butylammonium hydrogen sulfate, tetramethylammonium iodide , Tetramethylammonium hydroxide pentahydrate, tetramethylammonium hydroxide, methyltriethylammonium bromide, tetramethylammonium chloride monohydrate, tetramethylammonium bromide, Tetramethylammonium iodide, tetramethylammonium tetrafluoroborate, (n-hexyl) trimethylammonium bromide, phenyltrimethylammonium chloride, phenyltrimethylammonium iodide, benzyltrimethylammonium chloride, benzyltrimethylammonium iodide, benzyltrimethyl hydroxide Ammonium, (n-octyl) trimethylammonium bromide, (N-nonyl) trimethylammonium bromide, tetra-n-propylammonium bromide, phenyltriethylammonium iodide, (n-decyl) trimethylammonium bromide, benzyltriethyl chloride Ammonium, benzyltriethylammonium bromide, benzyltriethylammonium tetrafluoroborate, benzyltriethylammonium hydroxide , Trimethylammonium chloride (n-dodecyl) trimethylammonium bromide, benzyltri-n-propylammonium chloride, tetra-n-butylammonium bromide, tetra-n-butylammonium iodide, tetra-acetate n-Butylammonium, hydrogen sulfate tetra-n-butylammonium hydroxide, tetra-n-butylammonium hydroxide, tetra-n-butylammonium trifluoromethanesulfonate, (n-tetradecyl) trimethylammonium chloride, bromide (n-tetradecyl) Trimethylammonium, (n-hexadecyl) trimethylammonium bromide, tetra-n-pentylammonium chloride, tetra-n-pentylammonium iodide, benzyltri-n-butylammonium chloride, benzyltri-bromide n-butylammonium chloride, (n-hexadecyl) pyridinium chloride monohydrate, (n-hexadecyl) pyridinium bromide monohydrate, tetra-n-hexylammonium bromide, tetra-n-hexylammonium hydrogen sulfate, bromide Tetra-n-octylammonium, tetra-n-dodecylammonium iodide or tetra-n-dodecylammonium nitrate.

式(XIII)のホスホニウム塩の例は、塩化テトラ−n−ブチルホスホニウム、臭化テトラフェニルホスホニウム、塩化メチルトリ−n−オクチルホスホニウム、臭化メチルトリフェニルホスホニウム、臭化エチルトリ−n−オクチルホスホニウム、臭化テトラn−ブチルホスホニウム、塩化テトラフェニルホスホニウム、ヨウ化テトラフェニルホスホニウム、ヘキサフルオロアンチモン酸テトラフェニルホスホニウム、テトラフルオロホウ酸テトラフェニルホスホニウム、臭化(n−ヘキサデシル)トリ−n−ブチルホスホニウム又は塩化トリフェニルメチルトリフェニルホスホニウムである。   Examples of phosphonium salts of the formula (XIII) are tetra-n-butylphosphonium chloride, tetraphenylphosphonium bromide, methyltri-n-octylphosphonium chloride, methyltriphenylphosphonium bromide, ethyltri-n-octylphosphonium bromide, odor Tetra-n-butylphosphonium chloride, tetraphenylphosphonium chloride, tetraphenylphosphonium iodide, tetraphenylphosphonium hexafluoroantimonate, tetraphenylphosphonium tetrafluoroborate, (n-hexadecyl) tri-n-butylphosphonium bromide or trichloride Phenylmethyltriphenylphosphonium.

水不混和性又はやや水難溶性又は水不溶性の適当な溶媒は、例えば、脂肪族又は芳香族炭化水素であって、非置換であるか、又は1若しくはそれ以上の(C1−C4)−アルキル基、例えばメチル、又はフッ素、塩素及び臭素から選ばれる1若しくはそれ以上の置換基で置換されたもの、好ましくはトルエン、キシレン(純粋な異性体として又は異性体の混合物として)、エチルベンゼン、ヘプタン又はジクロロエタンである。前述の適当な溶媒の混合物も適当である。 Suitable water-immiscible or slightly poorly water-soluble or water-insoluble solvents are, for example, aliphatic or aromatic hydrocarbons, which are unsubstituted or one or more (C 1 -C 4 )- Alkyl groups such as methyl or substituted with one or more substituents selected from fluorine, chlorine and bromine, preferably toluene, xylene (as pure isomer or as a mixture of isomers), ethylbenzene, heptane Or dichloroethane. Mixtures of the aforementioned suitable solvents are also suitable.

p−トルエンスルホン酸誘導体(X)1モルに対しては、適当な溶媒0.6ないし1.1kgを使用するのが好ましい。式(IX)のアセチルピリジンオキシム塩100モルの反応においては、p−トルエンスルホン酸誘導体(X)99−150モル、更に好ましくは100−110モルを使用するのが好ましい。   It is preferable to use 0.6 to 1.1 kg of a suitable solvent for 1 mol of the p-toluenesulfonic acid derivative (X). In the reaction of 100 mol of the acetylpyridine oxime salt of formula (IX), it is preferable to use 99-150 mol, more preferably 100-110 mol, of p-toluenesulfonic acid derivative (X).

2相混合物の用語は、2つの液体相−アセチルピリジンオキシム塩(IX)を含む水性相及びp−トルエンスルホン酸誘導体(X)を含む溶媒相−の混合物を云う。相間移動触媒を使用する場合、それは水性相若しくは溶媒相中に存在するか、又は2相間に分割されていてもよい。2相混合物をバッチ式又は連続式工程操作の通常の方法で攪拌及び/又は混合して、相の良好な分配を確実にする。   The term two-phase mixture refers to a mixture of two liquid phases—an aqueous phase containing acetylpyridine oxime salt (IX) and a solvent phase containing p-toluenesulfonic acid derivative (X). If a phase transfer catalyst is used, it may be present in the aqueous or solvent phase or may be divided between the two phases. The two-phase mixture is agitated and / or mixed in the usual manner for batch or continuous process operations to ensure good distribution of the phases.

工程(b)におけるバッチ式操作の反応の温度は好ましくは0−50℃、更に好ましくは5−30℃であり、連続式操作においては0−60℃、更に好ましくは5−40℃である。   The reaction temperature of the batch operation in the step (b) is preferably 0-50 ° C, more preferably 5-30 ° C, and 0-60 ° C, more preferably 5-40 ° C in the continuous operation.

工程(c)においては、式(XI)のアセチルピリジントシルオキシムを含む溶媒相は、乾燥後又は先立つ乾燥なしで、アルカリ金属アルコキシド、アルカリ金属水酸化物、アルカリ土類金属アルコキシド又はアルカリ土類金属水酸化物及びアルコールの混合物中に計量して加え(ここで、“アルコキシド”とはR1-及び/又はR2-を意味し、そしてアルコールとはR1OH及び/又はR2OHを意味し、そしてR1及びR2は式(I)の化合物で定義した通りである)、そして式(I)の1−(ピリジニル)−1,1−ジアルコキシ−2−アミノエタン誘導体に変換する。 In step (c), the solvent phase comprising acetylpyridine tosyloxime of formula (XI) is dried after or without prior drying, alkali metal alkoxide, alkali metal hydroxide, alkaline earth metal alkoxide or alkaline earth metal. Metered into a mixture of hydroxide and alcohol (wherein “alkoxide” means R 1 O and / or R 2 O and alcohol means R 1 OH and / or R 2 OH) And R 1 and R 2 are as defined for compounds of formula (I)), and converted to 1- (pyridinyl) -1,1-dialkoxy-2-aminoethane derivatives of formula (I) To do.

工程(c)においては、式(XI)のアセチルピリジントシルオキシム100モルに対して、アルカリ金属アルコキシド99−500モル、更に好ましくは100−200モル;又はアルカリ金属水酸化物99−500モル、更に好ましくは100−300モル;又はアルカリ土類金属アルコキシド50−250モル、更に好ましくは50−100モル;又はアルカリ土類金属水酸化物50−250モル、更に好ましくは50−150モル使用するのが好ましい。   In step (c), 99-500 moles of alkali metal alkoxide, more preferably 100-200 moles, or 99-500 moles of alkali metal hydroxide, relative to 100 moles of acetylpyridine tosyloxime of formula (XI), Preferably 100-300 moles; or alkaline earth metal alkoxides 50-250 moles, more preferably 50-100 moles; or alkaline earth metal hydroxides 50-250 moles, more preferably 50-150 moles. preferable.

工程(c)においては、アルカリ金属水酸化物又はアルコキシド、特に水酸化リチウム、リチウムメトキシド、リチウムエトキシド、水酸化ナトリウム、ナトリウムメトキシド、ナトリウムエトキシド、水酸化カリウム、カリウムメトキシド、カリウムエトキシド、水酸化セシウム、セシウムメトキシド又はセシウムエトキシドを使用するのが好ましい。   In step (c), an alkali metal hydroxide or alkoxide, particularly lithium hydroxide, lithium methoxide, lithium ethoxide, sodium hydroxide, sodium methoxide, sodium ethoxide, potassium hydroxide, potassium methoxide, potassium ethoxy Preferably, cesium hydroxide, cesium hydroxide, cesium methoxide or cesium ethoxide are used.

アルコキシド及び/又はアルコールの選択は所望のアルコキシ基の導入に依存する。例えば、1−(ピリジニル)−1,1−ジメトキシ−2−アミノエタンの製造には、メタノール中のアルカリ金属若しくはアルカリ土類金属メトキシドの混合物、又はメタノール中のアルカリ金属水酸化物が使用される。R1とR2が酸素原子と一緒に環式ケタールを形成する化合物1−(ピリジニル)−1−([1,3]ジオキソラン)−2−アミノエタンの製造には、例えばグリコール中のアルカリ金属水酸化物が使用される。 The choice of alkoxide and / or alcohol depends on the introduction of the desired alkoxy group. For example, for the production of 1- (pyridinyl) -1,1-dimethoxy-2-aminoethane, a mixture of alkali metal or alkaline earth metal methoxide in methanol or an alkali metal hydroxide in methanol is used. For the preparation of the compound 1- (pyridinyl) -1-([1,3] dioxolane) -2-aminoethane in which R 1 and R 2 together with the oxygen atom form a cyclic ketal, for example, alkali metal water in glycol Oxides are used.

式(XI)のアセチルピリジンオキシムトシレート1モルに対して、対応するアルコール0.3−3kg、好ましくは0.5−1.5kgを使用するのが好ましい。変換は、例えば0−90℃、更に好ましくは10−60℃の温度範囲内で行われる。   It is preferred to use 0.3-3 kg, preferably 0.5-1.5 kg of the corresponding alcohol per mole of acetylpyridine oximutosylate of the formula (XI). The conversion is performed, for example, within a temperature range of 0-90 ° C, more preferably 10-60 ° C.

反応後、溶媒の一部をまず留去すると、p−トルエンスルホン酸塩副生物が室温で沈殿する。蒸留は通常の方法で行われる。留去した溶媒混合物(蒸留液)は直接工程(c)に再使用できる。   After the reaction, a part of the solvent is first distilled off, and p-toluenesulfonate by-product precipitates at room temperature. Distillation is carried out in the usual way. The solvent mixture distilled off (distilled liquid) can be directly reused in the step (c).

p−トルエンスルホン酸アルカリ金属又はアルカリ土類金属塩は通常の濾過方法で除去される。残りの溶媒部分は大気圧下又は好ましくは減圧下での蒸留により通常の方法で除去される。   The alkali metal or alkaline earth metal salt of p-toluenesulfonic acid is removed by a usual filtration method. The remaining solvent portion is removed in a conventional manner by distillation under atmospheric pressure or preferably under reduced pressure.

式(I)のアミノケタール誘導体は引き続き、場合によっては、真空蒸留若しくは精留により、又は前の蒸留で得られた蒸留残留物からの結晶により、高純度の形態で単離する。例えば、式(I)の化合物で、R1及びR2がそれぞれメチルである化合物は蒸留により精製することができる。 The amino ketal derivative of formula (I) is subsequently isolated in high purity form, optionally by vacuum distillation or rectification or by crystals from the distillation residue obtained in the previous distillation. For example, a compound of formula (I) in which R 1 and R 2 are each methyl can be purified by distillation.

真空蒸留又は精留における収量は、場合によっては蒸留残留物にフラックスを添加することにより改良することができる。フラックスの用語は、粘度が加熱により減少する液体又はワックス状固体であり、従って蒸留しようとする残留物の流動性を改良するが、同時に蒸留しようとする生成物よりもかなり高い沸点を有するものを云う。使用するフラックスは、例えば400よりも大きい分子量を有するポリエチレングリコール(例えばポリエチレングリコール600又はポリエチレングリコール1000)、パラフィン(Cn2n+2、ここでn>15)、多価アルコール類(1以上のOH基を有するアルコール、例えばグリセロール)又はエステル類、例えばセバシン酸ビス−2−エチルである。 The yield in vacuum distillation or rectification can optionally be improved by adding flux to the distillation residue. The term flux refers to a liquid or waxy solid whose viscosity is reduced by heating, thus improving the fluidity of the residue to be distilled, but at the same time having a considerably higher boiling point than the product to be distilled. say. The flux used is, for example, polyethylene glycol having a molecular weight greater than 400 (eg polyethylene glycol 600 or polyethylene glycol 1000), paraffin (C n H 2n + 2 , where n> 15), polyhydric alcohols (one or more Alcohols with OH groups, such as glycerol) or esters, such as bis-2-ethyl sebacate.

結晶は有機溶媒を使用して又は使用せずに通常の方法で行うことができる。溶融又は溶媒工程を使用し得る。     Crystallization can be carried out in the usual way with or without organic solvents. A melt or solvent process may be used.

本発明の方法の利点は、第1に、式(I)の化合物を遊離塩基として高純度且つ非常に良い収率で直接単離できることである。第2に、選択した反応条件により、実施するオキシム化及びトシル化反応が連続操作で可能となることである。連続操作は、安全性の観点から重要であるアセチルピリジントシルオキシムを固体として単離しなくとも、安全性の観点から関連性がある式(XI)の中間体を常に少量しか生成しない。何故なら、短時間の遅れ後、アセチルピリジントシルオキシムは連続装置内で、安全性の観点から重要でない式(I)のアミノケタールに直接変換されるからである。式(I)の化合物を高純度(97%を超える)及び高収率(使用したアセチルピリジンを基準にして75%を超える)で、工業規模に適する方法で遊離塩基の形態で製造することである。第4に、工程で純粋な形態又は混合物の形態で直接再使用することができる溶媒を使用するので、環境への影響が非常に少なく保たれることである。   The advantage of the process of the present invention is that, firstly, the compound of formula (I) can be isolated directly as the free base in high purity and in very good yield. Secondly, depending on the reaction conditions selected, the oximation and tosylation reactions to be carried out are possible in a continuous operation. Continuous operation always produces only a small amount of the intermediate of formula (XI) that is relevant from a safety standpoint, without isolating acetylpyridine tosyloxime, which is important from a safety standpoint, as a solid. This is because, after a short delay, the acetylpyridine tosyloxime is converted directly into the amino ketal of formula (I) which is not important from a safety point of view in a continuous apparatus. The preparation of the compound of formula (I) in high purity (greater than 97%) and high yield (greater than 75% based on the acetylpyridine used) in the form of the free base in a manner suitable for industrial scale. is there. Fourth, because the process uses a solvent that can be reused directly in pure form or in the form of a mixture, the environmental impact is kept very low.

実施例1:1−(3−ピリジニル)−1,1−ジメトキシ−2−アミノエタンの製造、方法1
1(a)反応器中で40%塩化ヒドロキシルアンモニウム溶液174g、3−アセチルピリジン121g及び33%水酸化ナトリウム溶液245gを3成分計量添加法(metering)で15−25℃の温度範囲内で反応させる。得られる3−アセチルピリジンオキシムのナトリウム塩溶液を塩化メチルトリブチルアンモニウム2gと反応させる。
Example 1: Preparation of 1- (3-pyridinyl) -1,1-dimethoxy-2-aminoethane, Method 1
1 (a) In a reactor, 174 g of 40% hydroxylammonium chloride solution, 121 g of 3-acetylpyridine and 245 g of 33% sodium hydroxide solution are reacted within a temperature range of 15-25 ° C. by a three-component metering method. . The resulting sodium salt solution of 3-acetylpyridine oxime is reacted with 2 g of methyltributylammonium chloride.

1(b)引き続き、この溶液を連続工程(部分的に取り出しながらスタテックミキサーを経るリサイクル法)で、塩化p−トルエンスルホニル193gの溶液及びトルエン655gと、内部温度35−38℃までで反応させる。次に得られた2相混合物を分離ゾーンを通過させ、そして溶媒相を水性相から分離する。   1 (b) Subsequently, this solution is reacted with a solution of 193 g of p-toluenesulfonyl chloride and 655 g of toluene in a continuous process (a recycling method through a static mixer while partially taking out) up to an internal temperature of 35-38 ° C. . The resulting biphasic mixture is then passed through a separation zone and the solvent phase is separated from the aqueous phase.

1(c)溶媒相をメタノール(又は1番目の溶媒蒸留からのメタノール/トルエン混合物、下記参照)940g及び30%ナトリウムメトキシド溶液216gからなる最初に充填した溶液中に直接流し込む。温度を20−40℃の範囲に保つ。反応溶液を更に5−10時間継続して反応させる。70−90℃及び大気圧でメタノールを反応混合物から、トルエンと共に共沸混合物として留去した(第1溶媒蒸留)。共沸溶媒混合物は上記の反応(上記参照)に再使用することができる。蒸留後、蒸留残留物を25℃に冷却し、p−トルエンスルホン酸ナトリウム塩を引き続き濾取し、そしてトルエン85gで洗う。引き続き濾液を減圧(ほぼ100−200ミリバール)下で内部温度ほぼ120−130℃までで蒸留することにより濃縮する。引き続きポリエチレングリコール600 10−20gを蒸留残留物に加え、1−(3−ピリジニル)−1,1−ジメトキシ−2−アミノエタンを1−10ミリバールで内部蒸発器温度100−160℃にて短いカラムを経て無色透明な液体として留去する。1−(3−ピリジニル)−1,1−ジメトキシ−2−アミノエタン157.3gを純度98−99%(滴定、HPLC−MS及びNMRにより参照標準と比較して決定)を有するものとして得る。これは使用した3−アセチルピリジンを基準として理論値の85%の収率に相当する。   1 (c) The solvent phase is poured directly into the initially charged solution consisting of 940 g of methanol (or methanol / toluene mixture from the first solvent distillation, see below) and 216 g of 30% sodium methoxide solution. Keep the temperature in the range of 20-40 ° C. The reaction solution is allowed to react for an additional 5-10 hours. Methanol was distilled off from the reaction mixture as an azeotrope with toluene at 70-90 ° C. and atmospheric pressure (first solvent distillation). The azeotropic solvent mixture can be reused in the above reaction (see above). After distillation, the distillation residue is cooled to 25 ° C., p-toluenesulfonic acid sodium salt is subsequently filtered off and washed with 85 g of toluene. The filtrate is subsequently concentrated by distillation under reduced pressure (approximately 100-200 mbar) to an internal temperature of approximately 120-130 ° C. Subsequently, 10-20 g of polyethylene glycol 600 is added to the distillation residue, and 1- (3-pyridinyl) -1,1-dimethoxy-2-aminoethane is added at 1-10 mbar and a short column at an internal evaporator temperature of 100-160 ° C. After that, it is distilled off as a colorless and transparent liquid. 157.3 g of 1- (3-pyridinyl) -1,1-dimethoxy-2-aminoethane are obtained as having a purity of 98-99% (determined by titration, HPLC-MS and NMR compared to a reference standard). This corresponds to a yield of 85% of theory based on the 3-acetylpyridine used.

実施例2:1−(3−ピリジニル)−1,1−ジメトキシ−2−アミノエタンの製造、方法2
2(a)反応器中で40%塩化ヒドロキシルアンモニウム溶液174g、3−アセチルピリジン121g及び33%水酸化ナトリウム溶液245gを3成分計量法(metering)で15−25℃の温度範囲内で反応させる。得られる3−アセチルピリジンオキシムのナトリウム塩溶液に塩化メチルトリブチルアンモニウム2gを加える。
Example 2: Preparation of 1- (3-pyridinyl) -1,1-dimethoxy-2-aminoethane, Method 2
2 (a) 174 g of 40% hydroxylammonium chloride solution, 121 g of 3-acetylpyridine and 245 g of 33% sodium hydroxide solution are reacted in a reactor in a temperature range of 15-25 ° C. by a three-component metering method. 2 g of methyltributylammonium chloride is added to the sodium salt solution of 3-acetylpyridine oxime obtained.

2(b)引き続き、この溶液を連続工程(部分的に取り出しながらスタテックミキサーを経るリサイクル法)で、塩化p−トルエンスルホニル193gの溶液及びトルエン655gと、内部温度35−38℃までで反応させる。次に得られた2相混合物を分離ゾーンを通過させ、そして溶媒相を水性相から分離する。   2 (b) Subsequently, this solution is reacted with a solution of 193 g of p-toluenesulfonyl chloride and 655 g of toluene at an internal temperature of 35 to 38 ° C. in a continuous process (a recycling method through a static mixer while partially taking out). . The resulting biphasic mixture is then passed through a separation zone and the solvent phase is separated from the aqueous phase.

2(c)溶媒相をメタノール(又は最初の溶媒蒸留からのメタノール/トルエン混合物、下記参照)940g及び30%水酸化ナトリウム48gからなる最初に充填した溶液中に直接流し込む。温度を20−40℃の範囲に保つ。反応溶液を更に5−10時間継続して反応させる。メタノールを反応混合物から、トルエンと共に共沸混合物として留去した(第1溶媒蒸留)。共沸溶媒混合物は上記の反応(上記参照)に再使用することができる。蒸留後、蒸留残留物を25℃に冷却し、p−トルエンスルホン酸ナトリウム塩を引き続き濾取し、そしてトルエン85gで洗う。引き続き濾液を減圧(ほぼ100−200ミリバール)下で内部温度ほぼ120−130℃までで蒸留することにより濃縮する。引き続きポリエチレングリコール600 10−20gを蒸留残留物に加え、1−(3−ピリジニル)−1,1−ジメトキシ−2−アミノエタンを1−10ミリバールで内部蒸発器温度100−160℃にて短いカラムを経て無色透明な液体として留去する。1−(3−ピリジニル)−1,1−ジメトキシ−2−アミノエタン148gを純度98−99%(滴定、HPLC−MS及びNMRにより参照標準と比較して決定)を有するものとして得る。これは使用した3−アセチルピリジンを基準として理論値の80%の収率に相当する。   2 (c) The solvent phase is poured directly into an initially charged solution consisting of 940 g of methanol (or methanol / toluene mixture from the first solvent distillation, see below) and 48 g of 30% sodium hydroxide. Keep the temperature in the range of 20-40 ° C. The reaction solution is allowed to react for an additional 5-10 hours. Methanol was distilled off from the reaction mixture as an azeotrope with toluene (first solvent distillation). The azeotropic solvent mixture can be reused in the above reaction (see above). After distillation, the distillation residue is cooled to 25 ° C., p-toluenesulfonic acid sodium salt is subsequently filtered off and washed with 85 g of toluene. The filtrate is subsequently concentrated by distillation under reduced pressure (approximately 100-200 mbar) to an internal temperature of approximately 120-130 ° C. Subsequently, 10-20 g of polyethylene glycol 600 is added to the distillation residue, and 1- (3-pyridinyl) -1,1-dimethoxy-2-aminoethane is added at 1-10 mbar and a short column at an internal evaporator temperature of 100-160 ° C. After that, it is distilled off as a colorless and transparent liquid. 148 g of 1- (3-pyridinyl) -1,1-dimethoxy-2-aminoethane are obtained having a purity of 98-99% (determined by titration, HPLC-MS and NMR compared to a reference standard). This corresponds to a yield of 80% of theory based on the 3-acetylpyridine used.

Claims (10)

式(I):
Figure 0004709741
[式中、R1及びR2はそれぞれ独立して(C1−C6)−アルキル(ここで該アルキル基は直鎖又は分岐鎖であってよい)であるか、又はR1及びR2は酸素原子と一緒に環式ケタール(ここでR1及びR2は一緒になって(C2−C4)−アルキリデン基である)を形成し、ピリジン基は2−、3−又は4−位で置換されている]の1−(ピリジニル)−1,1−ジアルコキシ−1−アミノエタン誘導体の製造法であって、
工程(a)で、式(V)のアセチルピリジンを、ヒドロキシルアンモニウム化合物の水溶液、又はヒドロキシルアミンの水溶液を用いて、Mn+を含む無機塩基を添加して、式(IX)のアセチルピリジンオキシム金属塩(ここでnは1又は2、そしてMn+はアルカリ金属又はアルカリ土類金属イオンである)に変換し、
Figure 0004709741
工程(b)で、式(IX)のアセチルピリジンオキシム金属塩を、水不混和性又はわずかに水可溶性又は水不溶性の適当な溶媒中の、脱離基Yを含むp−トルエンスルホン酸誘導体(X)
Figure 0004709741
(式中、YはF、Cl又はBrである)の溶液と反応させて、式(XI)
Figure 0004709741
のアセチルピリジントシルオキシムを得るもので、この反応は水と適当な溶媒との2相混合物中で、場合によっては1種又はそれ以上の相間移動触媒の使用により進行させ、そして
工程(c)で、行程(b)で得られた化合物(XI)を含む溶媒相を、アルカリ金属アルコキシド、アルカリ金属水酸化物、アルカリ土類金属アルコキシド又はアルカリ土類金属水酸化物とアルコールとの混合物に直接加えることによりこの式(XI)のアセチルピリジントシルオキシムを、式(I)の化合物に変換し(ここで、“アルコキシド”とはR1-及び/又はR2-を意味し、そしてアルコールとはR1OH及び/又はR2OHを意味し、そしてR1及びR2はそれぞれ式(I)の化合物で定義した通りである)、
そしてこの工程(a)ないし(c)のそれぞれを独立して連続的に又はバッチ式で行うことを特徴とする上記の製造法。
Formula (I):
Figure 0004709741
[Wherein R 1 and R 2 are each independently (C 1 -C 6 ) -alkyl (wherein the alkyl group may be linear or branched), or R 1 and R 2 Together with an oxygen atom form a cyclic ketal where R 1 and R 2 together are a (C 2 -C 4 ) -alkylidene group, and the pyridine group is 2-, 3- or 4- Substituted at the position] of 1- (pyridinyl) -1,1-dialkoxy-1-aminoethane derivative,
In step (a), an acetylpyridine oxime metal of formula (IX) is added to the acetylpyridine of formula (V) by adding an inorganic base containing M n + using an aqueous solution of hydroxylammonium compound or an aqueous solution of hydroxylamine. Converted to a salt, where n is 1 or 2, and M n + is an alkali metal or alkaline earth metal ion;
Figure 0004709741
In step (b), the acetylpyridine oxime metal salt of formula (IX) is converted into a p-toluenesulfonic acid derivative containing a leaving group Y in a suitable solvent that is water-immiscible or slightly water-soluble or water-insoluble ( X)
Figure 0004709741
Reaction with a solution of formula (XI) wherein Y is F, Cl or Br.
Figure 0004709741
Wherein the reaction proceeds in a two-phase mixture of water and a suitable solvent, optionally by use of one or more phase transfer catalysts, and in step (c) The solvent phase containing the compound (XI) obtained in step (b) is added directly to the alkali metal alkoxide, alkali metal hydroxide, alkaline earth metal alkoxide or mixture of alkaline earth metal hydroxide and alcohol. This acetylpyridine tosyl oxime of formula (XI) is converted to a compound of formula (I) (where “alkoxide” means R 1 O and / or R 2 O and alcohol and Means R 1 OH and / or R 2 OH, and R 1 and R 2 are each as defined for compounds of formula (I)),
And said manufacturing method characterized by performing each of this process (a) thru | or (c) independently continuously or batchwise.
ピリジン基が3−位で置換されている、請求項1記載の製造法。  The process according to claim 1, wherein the pyridine group is substituted at the 3-position. 1及びR2がそれぞれ(C1−C6)−アルキルである、請求項1又は2記載の製造法。The production method according to claim 1 or 2, wherein R 1 and R 2 are each (C 1 -C 6 ) -alkyl. 工程(a)で、ヒドロキシルアミン、塩化ヒドロキシルアンモニウム又は硫酸ヒドロキシルアンモニウムを使用する、請求項1〜3のいずれか1項記載の製造法。  The process according to any one of claims 1 to 3, wherein hydroxylamine, hydroxylammonium chloride or hydroxylammonium sulfate is used in step (a). 工程(a)で、Mn+がLi+、Na+、K+又はCa2+を意味する、請求項1〜4のいず
れか1項記載の製造法。
The process according to any one of claims 1 to 4, wherein in step (a), M n + means Li + , Na + , K + or Ca 2+ .
工程(a)で、Mn+を含む無機塩基が水酸化リチウム、水酸化ナトリウム、炭酸ナトリウム、炭酸水素ナトリウム、水酸化カリウム、炭酸カリウム又は水酸化カルシウムである、請求項1〜5のいずれか1項記載の製造法。The inorganic base containing M n + in step (a) is lithium hydroxide, sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, potassium hydroxide, potassium carbonate or calcium hydroxide. The manufacturing method of description. 工程(b)で、脱離基YがClである、請求項1〜6のいずれか1項記載の製造法。  The manufacturing method of any one of Claims 1-6 whose leaving group Y is Cl in a process (b). 工程(b)で、相間移動触媒が式(XII)の第4級アンモニウム塩、又は式(XIII)のホスホニウム塩:
Figure 0004709741
[式中、R3ないしR10は同じ又は異なり、そしてそれぞれ独立して
a)直鎖又は分岐鎖の(C1−C20)−アルキル、
b)ベンジル、又は
c)フェニル、そして
-はアニオンである]である、請求項1〜7のいずれか1項記載の製造法。
In step (b), the phase transfer catalyst is a quaternary ammonium salt of formula (XII) or a phosphonium salt of formula (XIII):
Figure 0004709741
[Wherein R 3 to R 10 are the same or different and are each independently a) a linear or branched (C 1 -C 20 ) -alkyl,
b) benzyl, or c) phenyl and X, - is a anion emission is] The process according to any one of claims 1-7.
工程(c)で、水酸化リチウム、リチウムメトキシド、リチウムエトキシド、水酸化ナトリウム、ナトリウムメトキシド、ナトリウムエトキシド、水酸化カリウム、カリウムメトキシド、カリウムエトキシド、水酸化セシウム、セシウムメトキシド又はセシウムエトキシドを使用する、請求項1〜8のいずれか1項記載の製造法。  In step (c), lithium hydroxide, lithium methoxide, lithium ethoxide, sodium hydroxide, sodium methoxide, sodium ethoxide, potassium hydroxide, potassium methoxide, potassium ethoxide, cesium hydroxide, cesium methoxide or The manufacturing method of any one of Claims 1-8 using a cesium ethoxide. 工程(c)で、式(XI)のアセチルピリジントシルオキシムを先立って乾燥せずに使用する、請求項1〜9のいずれか1項記載の製造法。  The process according to any one of claims 1 to 9, wherein in step (c), the acetylpyridine tosyloxime of formula (XI) is used without prior drying.
JP2006501606A 2003-02-11 2004-01-27 Process for producing pyridine-substituted aminoketal derivatives Expired - Fee Related JP4709741B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10305391.3 2003-02-11
DE10305391A DE10305391A1 (en) 2003-02-11 2003-02-11 Preparation of 1-(pyridinyl)-1,1-dialkoxy-1-aminoethane derivatives involves reacting acetylpyridine tosyl oxime with mixture of alkali metal alkoxide or hydroxide or alkaline earth metal alkoxide or hydroxide with alcohol
PCT/EP2004/000640 WO2004072026A2 (en) 2003-02-11 2004-01-27 Process for preparing pyridine-substituted amino ketal derivatives

Publications (3)

Publication Number Publication Date
JP2006518716A JP2006518716A (en) 2006-08-17
JP2006518716A5 JP2006518716A5 (en) 2011-01-27
JP4709741B2 true JP4709741B2 (en) 2011-06-22

Family

ID=32730947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006501606A Expired - Fee Related JP4709741B2 (en) 2003-02-11 2004-01-27 Process for producing pyridine-substituted aminoketal derivatives

Country Status (20)

Country Link
EP (1) EP1601648A2 (en)
JP (1) JP4709741B2 (en)
KR (1) KR101114893B1 (en)
CN (1) CN100393701C (en)
AR (1) AR043132A1 (en)
AU (1) AU2004212038B2 (en)
BR (1) BRPI0407349A (en)
CA (1) CA2514255C (en)
CO (1) CO5690583A2 (en)
DE (1) DE10305391A1 (en)
HK (1) HK1086007A1 (en)
IL (1) IL169900A (en)
MX (1) MXPA05007961A (en)
NO (1) NO332353B1 (en)
NZ (1) NZ541735A (en)
PL (1) PL376654A1 (en)
RU (1) RU2336271C2 (en)
TW (1) TWI316054B (en)
WO (1) WO2004072026A2 (en)
ZA (1) ZA200505298B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115477926B (en) * 2022-09-15 2024-06-25 江苏科技大学 Phase change material and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258457A (en) * 1987-03-31 1988-10-25 ワーナー‐ランバート・コンパニー Tetrahydropyridine oxime choline agonist and therapeutic method
US5792871A (en) * 1996-07-22 1998-08-11 Merck & Co., Inc. Process for N-Boc-N-(R)-2(3-pyridyl)-2-hydroxy-ethyl)-N-2(4-aminophenyl)ethyl amine and 2-(4-aminophenyl)-N-2-(2(R)-hydroxy-2-phyridin-S-yl-ethyl)acetamide
JP2002520325A (en) * 1998-07-09 2002-07-09 アベンティス ファルマ ソシエテ アノニム Method for producing 4- (3-pyridinyl) -1H-imidazole and intermediate used

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746669A (en) * 1985-12-23 1988-05-24 Merck & Co., Inc. Substituted thiazoles as immunoregulants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258457A (en) * 1987-03-31 1988-10-25 ワーナー‐ランバート・コンパニー Tetrahydropyridine oxime choline agonist and therapeutic method
US5792871A (en) * 1996-07-22 1998-08-11 Merck & Co., Inc. Process for N-Boc-N-(R)-2(3-pyridyl)-2-hydroxy-ethyl)-N-2(4-aminophenyl)ethyl amine and 2-(4-aminophenyl)-N-2-(2(R)-hydroxy-2-phyridin-S-yl-ethyl)acetamide
JP2002520325A (en) * 1998-07-09 2002-07-09 アベンティス ファルマ ソシエテ アノニム Method for producing 4- (3-pyridinyl) -1H-imidazole and intermediate used

Also Published As

Publication number Publication date
ZA200505298B (en) 2008-01-30
RU2336271C2 (en) 2008-10-20
JP2006518716A (en) 2006-08-17
WO2004072026B1 (en) 2004-11-18
CA2514255C (en) 2012-01-24
NZ541735A (en) 2008-06-30
HK1086007A1 (en) 2006-09-08
TWI316054B (en) 2009-10-21
CN1747932A (en) 2006-03-15
NO20054167D0 (en) 2005-09-07
AU2004212038B2 (en) 2010-11-25
WO2004072026A3 (en) 2004-09-30
IL169900A (en) 2010-12-30
DE10305391A1 (en) 2004-08-19
NO332353B1 (en) 2012-09-03
NO20054167L (en) 2005-10-31
AR043132A1 (en) 2005-07-20
AU2004212038A1 (en) 2004-08-26
WO2004072026A2 (en) 2004-08-26
KR20050101205A (en) 2005-10-20
CO5690583A2 (en) 2006-10-31
BRPI0407349A (en) 2006-01-10
CA2514255A1 (en) 2004-08-26
PL376654A1 (en) 2006-01-09
CN100393701C (en) 2008-06-11
RU2005128281A (en) 2006-02-10
IL169900A0 (en) 2007-07-04
KR101114893B1 (en) 2012-03-06
EP1601648A2 (en) 2005-12-07
MXPA05007961A (en) 2005-09-20
TW200504020A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
US20100197928A1 (en) Method for preparing disubstituted piperidine and intermediates
CN106660959B (en) The preparation method of 3- hydroxy-picolinic acid
US20140121371A1 (en) Processes and reagents for making diaryliodonium salts
US6495685B1 (en) Process for preparing piperazine derivatives
JP4709741B2 (en) Process for producing pyridine-substituted aminoketal derivatives
US10954191B2 (en) Process for the preparation of glycopyrrolate tosylate
US10053420B2 (en) Processes for the preparation of compounds, such as 3-arylbutanals, useful in the synthesis of medetomidine
US8680332B2 (en) Disubstituted-aminodifluorosulfinium salts, process for preparing same and method of use as deoxofluorination reagents
US6916934B2 (en) Process for preparing pyridine-substituted amino ketal derivatives
US20180186706A1 (en) Process for manufacturing 1-cyclopropyl-naphthalenes
JP5078211B2 (en) Method for producing heterocyclic compound
JP3907787B2 (en) Method for producing benzoic acid derivative
EP1896397B1 (en) Process for producing ethers
JP5482233B2 (en) Method for producing diaryl disulfide compound
CN108822101B (en) Method for synthesizing benzhydrylquinuclidinone by Michael addition
EP2650282B1 (en) Process for producing substituted methylamine compound and triazine derivative
JP4393839B2 (en) Preparation of 1,3-di-halo substituted benzene derivatives
WO2000076976A1 (en) Process for the production of 2-pyridylpyridine derivatives
EP2723727B1 (en) Method for industrially preparing nitrogen substituted amino-5,6,7,8-tetrahydronaphthol
JPS59199651A (en) Synthesis of methylglyoxal acetal
JPH0753702B2 (en) Method for separating aminoketones
TW201823210A (en) Method of preparing benzyl 4-amino-3-chloro-5-fluoro-6-(4-chloro-2-fluoro-3-methoxyphenyl)picolinate
JPH08283222A (en) Production of substituted amine
WO2008044701A1 (en) Method for producing piperidin-4-one derivative
JPH083126A (en) Production of n,o-dimethylhydroxylamine

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101203

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110318

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees